Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Olmesartan recalled?

Yes — there is an active recall. 3 ongoing FDA recalls mention Olmesartan (16 total). Check the affected lots below.

Most common reason: Temperature excursion (8 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Olmesartan. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Olmesartan recalls in 2026

2 initiated in 2026, 16 in total — newest first
Class II · Moderate risk

Olmesartan Medoxomil Tablets 20 mg

cGMP Deviations; Olmesartan Medoximil Tablets 20 mg was released in error with alternate API source prior to filing and approval of Prior Approval Supplement.

Terminated cGMP deviation Ascend Laboratories LLC NDC 67877-446-90 D-0828-2020
Class III · Low risk

Amlodipine and Olmesartan Medoxomil Tablets

Discoloration: This product is being recalled due to a confirmed pharmacist report that tablets from this lot were a pink color instead of cream (peach).

Terminated Failed specification Aurobindo Pharma USA Inc. NDC 65862-855-30 D-0289-2019
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-107-30 D-1508-2014
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-106-30 D-1507-2014
Class II · Moderate risk

Benicar Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping.

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-104-30 D-1506-2014
Class II · Moderate risk

Tribenzor Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-116-30 D-1504-2014
Class II · Moderate risk

Benicar HCT Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-105-30 D-1503-2014
Class II · Moderate risk

Benicar Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-103-30 D-1502-2014
Class II · Moderate risk

Azor Tablets

Temperature Abuse; various products were not stored at Controlled Room Temperature as per USP guidelines during shipping

Terminated Temperature excursion Daiichi Sankyo Pharma Development NDC 65597-113-30 D-1501-2014